By Timothy S. Donahue
- Transparency push: FDA has unveiled a new roadmap to make more of the agency’s regulatory reasoning, application information, and inspection records public.
- Tobacco question: The roadmap does not specifically promise expanded disclosure of PMTA records or tobacco marketing decisions.
- PMTA reset: The initiative comes as the FDA is considering significant changes to the PMTA framework to make the pathway clearer and more predictable.
FDA wants to let more sunshine in. The tobacco industry wonders whether CTP is kept in the dark.
The U.S. Food and Drug Administration has unveiled a new Transparency Roadmap that calls for greater disclosure of regulatory decisions and inspection records across the agency, potentially raising questions about how much additional visibility tobacco and nicotine companies could eventually gain into FDA decision-making.
The roadmap, released by Lowell M. Zeta, the FDA’s acting chief of staff, deputy commissioner for strategic initiatives, and special counsel, outlines transparency milestones achieved in fiscal 2026 and priorities for fiscal 2027.
“An agency that is open about its reasoning and processes is one that innovators can navigate with confidence, that investors can trust with capital, and that patients can rely on for honest answers,” Zeta wrote.
The FDA said the roadmap reflects its intention to “maximize disclosure” where appropriate while protecting intellectual property, trade secrets, and confidential commercial information.
For tobacco manufacturers, however, exactly how much of that sunlight will reach CTP remains unclear.
The roadmap does not specifically announce new disclosure requirements for Premarket Tobacco Product Applications (PMTAs) or promise to publish pending tobacco applications, deficiency letters, marketing denial orders, or other CTP review documents that are not already public.
Much of the roadmap’s application-specific disclosure agenda focuses on drugs and biologics, including complete response letters, Investigational New Drug Applications, clinical study reports, and greater disclosure of New Drug Applications and Biologics License Applications.
Still, the philosophy behind the initiative closely mirrors the transparency concerns that have followed the tobacco premarket review process.
The FDA already publishes documents related to some tobacco marketing decisions, including redacted marketing granted and denial orders and decision summaries. The agency says it works to post relevant documents for marketing orders, although redactions of confidential commercial information and accessibility reviews can delay publication.
Pending tobacco applications are another issue.
FDA says its searchable tobacco products database does not list products with pending applications and, in general, that the agency cannot provide information about those applications because of protections for confidential commercial information.
CTP has previously acknowledged calls for greater transparency.
In 2024, the center resumed publishing internal scientific review policy memoranda on the PMTA process, following recommendations from the Reagan-Udall Foundation’s operational evaluation of CTP. “We’ve heard loud and clear from stakeholders that opportunities exist to enhance the center’s transparency,” then-CTP Director Brian King said at the time.
FDA said that releasing the previously internal memoranda was intended to provide greater clarity about the premarket review process and that it committed to releasing additional batches as appropriate.
The latest transparency initiative also comes as the FDA considers a broader overhaul of the PMTA framework.
In September, the FDA said it intends to evaluate changes to the current PMTA rules based on its experience implementing the framework, the growth of a large illicit and unregulated market, the pace of new product introductions, and litigation related to the regulations.
The agency said a revised framework should provide greater clarity and predictability for applicants while maintaining the statutory requirement that new tobacco products be “appropriate for the protection of public health” (APPH).
The review builds on other CTP efforts to move away from what Director Bret Koplow has described as a “one-size-fits-all” approach to tobacco product review.
CTP has been testing more tailored approaches, including a nicotine pouch pilot to accelerate the review of qualifying applications and a supplemental PMTA pilot for certain modifications to already-authorized products.
FDA has also highlighted the sheer scale of the regulatory workload. CTP said earlier this year that it had received nearly 27 million PMTAs since the application requirement took effect and was working to streamline reviews and reduce its backlog.
Against that backdrop, greater visibility into how the FDA reaches its tobacco decisions could be particularly significant for manufacturers navigating a regulatory system the agency itself is now reconsidering.
The new agency-wide roadmap describes transparency as a means for regulated companies to understand the FDA’s regulatory science, learn from previous decisions, and avoid mistakes that can consume resources and delay products.
The FDA said that disclosure can allow sponsors and researchers to “observe and learn from the FDA’s evidentiary reasoning across prior decisions” and help companies “better navigate evolving regulatory science in development and avoid common pitfalls.”
That rationale could be particularly significant for tobacco companies navigating the PMTA process, although the FDA did not state in the roadmap that those disclosure initiatives would be extended to tobacco applications.
One part of the roadmap may have broader implications. FDA said it plans to expand public access to inspection records by proactively publishing redacted Form 483s and additional establishment inspection reports where appropriate.
Form 483s document conditions or practices observed during FDA inspections that investigators believe may indicate violations of agency requirements. “Greater predictability in how and when inspection findings become public supports proactive remediation and a shared understanding of regulatory expectations,” FDA said.
FDA’s current public inspection-observation datasets cover several product and program areas, but its public webpage does not list tobacco as a separate category in those datasets. The new roadmap likewise does not explicitly state that tobacco establishment Form 483s or inspection reports will be included in the expanded publication initiative.
For now, that leaves an important distinction.
The FDA has laid out a broad commitment to make its regulatory reasoning and compliance work more visible, even as it reconsiders how tobacco products move through the PMTA process.
It has not yet been said how far either effort will change what tobacco manufacturers and the public can see. For an industry that has spent years trying to understand what the FDA expects from a successful PMTA, that may be the transparency question that matters most.





